Publications by authors named "I L Conceicao"
Importance: There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN.
Objective: To present the long-term efficacy and safety of patisiran in adults with hATTR-PN.
Background: The NEURO-TTRansform trial showed that after 66 weeks of treatment, eplontersen significantly reduced neuropathic impairment and improved quality of life (QoL) in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). In this secondary analysis from NEURO-TTRansform, autonomic impairment, and the impact of eplontersen on autonomic impairment progression was evaluated through 85 weeks in patients randomised to eplontersen ( = 144) versus external placebo ( = 60; through Week 66 from the NEURO-TTR trial).
Methods: Change from baseline in modified Neuropathy Impairment Score +7 (mNIS+7) composite score, Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score, and the Neuropathy Symptoms and Change (NSC) total score was evaluated.
Background: The presence of potato cyst nematodes (PCN) causes a significant risk to potato crops globally, leading to reduced yields and economic losses. While the plant Solanum sisymbriifolium is known for its resistance to PCN and can be used as a trap crop, the molecular mechanisms behind this resistance remain poorly understood. In this study, genes differentially expressed were identified in control and infected plants during the early stages of the S.
View Article and Find Full Text PDFArticle Synopsis
- * A case report details a 21-year-old woman with LEMS who initially improved with treatment but developed psychotic symptoms leading to steroid discontinuation and later experienced worsening health, including respiratory distress and difficulties with swallowing.
- * After undergoing plasmapheresis and starting rituximab, her muscle strength partially improved, but her psychiatric symptoms remained, indicating a potential separate psychiatric issue alongside her neuromuscular condition.
Article Synopsis
- * A study of 109 patients revealed a median diagnostic delay of 1262 days, with no significant differences noted over the decades in terms of delay.
- * The findings suggest a need for increased awareness among healthcare professionals about the diverse symptoms of ATTRv amyloidosis and the significance of family history in diagnosis.